With days or weeks before the final interim review for Geron's (GERN) Imetelstat in the iMbark Myelofibrosis "MF" trial, its time for investors to consider the outcome of that review as it relates to not only the future of the iMbark trial, but also the future of the Johnson & Johnson (JNJ) / Geron collaboration along with the related $900MM+ in milestone payments for Geron.
Even though Geron has not promised to disclose full details of the review, investors should shortly find out if the FDA agrees to the extension of treatment for patients in iMbark beyond the April 2018 protocol specified end date of the Phase 2 trial. Looking at what JNJ is recently publishing and saying about Imetelstat, however, should give confidence and comfort investors about the future partnership and a bright future for Geron.
READ FULL ARTICLE HERE

